OncoZenge AB (FRA:8LY) OCF Yield %: -19.55 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8LY OncoZenge AB FRA:8LY
26 GF Score
Price €0.61
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB OCF Yield %?

OncoZenge AB FRA:8LY -4.98% 26 OCF Yield % is -19.55 as of Jul. 27, 2026. GuruFocus rates FRA:8LY with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, OncoZenge AB ranks worse than 67.12% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, OncoZenge AB's Trailing 12-Month Cash Flow from Operations is €-2.03 Mil, and Market Cap is €10.12 Mil. Therefore, OncoZenge AB's OCF Yield % for today is -19.55%.

The historical rank and industry rank for OncoZenge AB's OCF Yield % or its related term are showing as below:

FRA:8LY' s OCF Yield % Range Over the Past 10 Years
Min: -20.86   Med: -13.98   Max: -6.77
Current: -19.55


During the past 6 years, the highest OCF Yield % of OncoZenge AB was -6.77%. The lowest was -20.86%. And the median was -13.98%.

FRA:8LY's OCF Yield % is ranked worse than
67.12% of 1408 companies
in the Biotechnology industry
Industry Median: -8.695 vs FRA:8LY: -19.55

OncoZenge AB's OCF Margin % for the quarter that ended in Mar. 2026 was %.


OncoZenge AB OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


OncoZenge AB OCF Yield % Related Terms


OncoZenge AB OCF Yield % Historical Data

* Premium members only.

The historical data trend for OncoZenge AB's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoZenge AB OCF Yield % Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -3.53 -36.44 -52.25 -19.96 -15.55

OncoZenge AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.38 1.33 -18.96 -37.54 -58.81

FRA:8LY vs VRTX, REGN, RVMD: OCF Yield % Comparison

For the Biotechnology subindustry, OncoZenge AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoZenge AB OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's OCF Yield % distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's OCF Yield % falls into.


FRA:8LY
26GF Score
OncoZenge AB FRA:8LY
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

OncoZenge AB's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-1.2 / 7.71467
=-15.55%

OncoZenge AB's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-1.008 * 4 / 6.855424
=-58.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -19.55 mean?
OncoZenge AB (FRA:8LY) has a OCF Yield % of -19.55 as of Jul. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #945 out of 1408 companies in the Biotechnology industry, placing it in the top 67.1%.
Is OncoZenge AB's OCF Yield % too high?
OncoZenge AB's current OCF Yield % is -19.55. Based on the distribution chart, OncoZenge AB ranks #945 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #945 out of 1408 companies for OCF Yield %. This places OncoZenge AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on OncoZenge AB and its competitors. OncoZenge AB's current OCF Yield % is -19.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (FRA:8LY) has a current OCF Yield % of -19.55. The current OCF Yield % is -19.55. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For OncoZenge AB (FRA:8LY), the current OCF Yield % is -19.55 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoZenge AB Business Description

Other Exchanges ONCOZ:Sweden
Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for FRA:8LY

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price